Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.09.2022 | Case report

Infliximab

Vasculitis: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Reid J, et al. REAL WORLD OUTCOMES OF NON-MEDICAL SWITCHING OF INFLIXIMAB BIOSIMILAR IN BRITISH COLUMBIA FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD). Journal of the Canadian Association of Gastroenterology 5 (Suppl. 1): 23-24 abstr. A149, Mar 2022. Available from: URL: http://doi.org/10.1093/jcag/gwab049.148 [abstract] Reid J, et al. REAL WORLD OUTCOMES OF NON-MEDICAL SWITCHING OF INFLIXIMAB BIOSIMILAR IN BRITISH COLUMBIA FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD). Journal of the Canadian Association of Gastroenterology 5 (Suppl. 1): 23-24 abstr. A149, Mar 2022. Available from: URL: http://​doi.​org/​10.​1093/​jcag/​gwab049.​148 [abstract]
Metadaten
Titel
Infliximab
Vasculitis: case report
Publikationsdatum
01.09.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-24055-5

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Antineoplastics

Case report

Multiple drugs

Case report

Heparin